SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.
Gregg Honigblum, Chief Investment Officer, and Ryan Elmore, President of SINTX, will deliver a company presentation and participate in one-on-one meetings with investors throughout the conference. The presentation will highlight SINTX’s progress in commercializing its FDA-cleared SINAPTIC® Foot & Ankle Implant System, expanding adoption of its proprietary silicon nitride technology, growing its contract manufacturing activities, and advancing strategic initiatives designed to broaden the Company’s commercial opportunities and support long-term shareholder value.
Event Details
Conference: 28th Annual H.C. Wainwright Global Investment Conference
Date: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York City
Investors interested in scheduling a one-on-one meeting with SINTX management are encouraged to contact their H.C. Wainwright representative, email meetings@hcwco.com, or contact SINTX Investor Relations at IR@sintx.com.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC® Foot & Ankle Implant System for reconstructive surgery.
SINTX Contacts:
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
What 7 Key Market Indicators Are Telling Investors Right Now
Don’t Overlook the Income Side of Fixed Income
United States